ETBX 021

Drug Profile

ETBX 021

Alternative Names: Ad5 [E1-, E2b-]-HER2/neu Vaccine; ETBX-021

Latest Information Update: 30 Dec 2016

Price : $50

At a glance

  • Originator Etubics Corporation
  • Developer NantBioScience
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Breast cancer

Most Recent Events

  • 01 Dec 2016 Phase-I clinical trials in Breast cancer (Late-stage disease, Metastatic disease) in USA (Parenteral, Suspension) (NCT02751528)
  • 02 May 2016 NantBioScience plans a phase I trial for breast cancer in USA (NCT02751528).
  • 29 Apr 2016 Etubics receives SBIR grant from NCI for ETBX-021 development in Breast cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top